Contents
Academic literature on the topic 'UCG 90-20'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'UCG 90-20.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "UCG 90-20"
1
Choque-Conde, Esteban, Hans Franklin Mercado-Ríos, Alberto Gutierrez, and Jhonny Ojeda-Choque. "Efecto del abono verde y fertilización química en tres variedades de Caña de Azúcar en suelos franco arenosos del municipio Fernández Alonso, Santa Cruz, Bolivia." Revista de Investigación Agropecuaria y Forestal Boliviana - RIAFB 6, no. 11 (2019): 8–21. https://doi.org/10.5281/zenodo.8215540.
Full textAbstract:
La investigación fue realizada en los predios del Centro Nacional de la Caña de Azúcar (CENACA), localizado en el municipio Fernández Alonso, departamento Santa Cruz, país Bolivia, conducidos bajo el diseño estadístico de parcelas sub divididas de tres niveles (abonos verdes, variedades de caña de azúcar y, parcelas con y sin fertilización), en el marco del objetivo de Determinar la respuesta de tres variedades de caña de azúcar -RBB 77- 26, UCG 90-20 y UCG 96-10- sobre rastrojos de abonos verdes (crotalaria, sorgo y barbecho). Como variables de respuesta se evaluaron la número de tallos (NT), altura de tallo molible (ATM), diámetro de tallo (DT) y peso de tallo molible (PTM), colateralmente, el porcentaje de sacarosa (PS) y Rendimiento (Y). Los resultados estadísticos indican una diferencia significativa entre tratamientos, mediante una comparación de medias, según la prueba DMS (diferencia mínima significativa) al 5% de probabilidad. Según los resultados, el rastrojo de crotalaria tuvo mayor efecto en cuanto al NT, ATM y PTM en relación al rastrojo de sorgo. Los óptimos resultados se dieron sobre los rastrojo de crotalaria tanto en el rendimiento y niveles de caña de azúcar, destacando la variedad UCG 96-10, seguido de la variedad UCG 90-20 y RBB 77-26 respectivamente, además, de existir respuesta a la fertilización con N, P y K.
2
Huynh, Quoc Dung, Hoang Nhat Huy Luong, Nhat Tan Ngo, et al. "Recycling used coffee grounds as fine aggregate in alkali-activated lightweight non-load-bearing composites." CTU Journal of Innovation and Sustainable Development 17, Special issue: ETMD (2025): 24–31. https://doi.org/10.22144/ctujoisd.2025.004.
Full textAbstract:
Coffee is one of the most consumed drinks, which releases large amounts of used coffee grounds (UCG), causing environmental problems. Thus, UCG was re-used in combination with bottom ash (BA) as fine aggregates in making alkali-activated non-load-bearing lightweight composites (ANLC) in this study. To evaluate the effect of UCG on the properties of ANLC, seven ANLC mixtures with UCG/BA ratios of 0/100, 5/95, 10/90, 15/85, 20/80, 25/75, and 30/70 were prepared. Results showed that the properties of ANLC were influenced significantly by UCG contents. Indeed, an increase in UCG content led to a decrease in dry density, strength, and drying shrinkage while increasing the ANLC’s water absorption, except for the specimen with 5% UCG incorporation. Correlations among properties of ANLC were established and the potential applications of ANLC in real practice were also suggested, proving that the ANLC could be applied to non-load-bearing elements. Among the mixtures, the 28-day ANLC specimen containing 5% UCG exhibited the highest flexural and compressive strengths of 7.12 MPa and 39.4 MPa, respectively, and the lowest water absorption of 10.29% with the relatively low dry density of 1671 kg/m3, indicating the feasibility of using UCG as fine aggregate in the production and application of ANLC.
3
Yoshimi, Akihide, Yasuhito Nannya, Kumi Oshima, et al. "Reduced Cyclophosphamide Combined with Etoposide and Total Body Irradiation as a Conditioning Regimen for Patients with Impaired Cardiac Function Undergoing Allogeneic Stem Cell Transplantation." Blood 110, no. 11 (2007): 2000. http://dx.doi.org/10.1182/blood.v110.11.2000.2000.
Full textAbstract:
Abstract Cardiac toxicity due to conditioning regimens is a critical problem in the hematopoietic stem cell transplantation (HSCT). High-dose cyclophosphamide, which is a major component of conventional myeloablative regimens, is considered to be a main cause of cardiac toxicity. Although reduced intensity conditioning regimens have been developed in order to diminish regimen related toxicities for patients with pre-transplant co-morbidity, their anti-neoplastic effects have been revealed to be insufficient especially for patients with acute lymphoblastic leukemia. Therefore, it is imperative to establish an alternative preparative regimen with myeloablative intensity for patients with impaired pre-transplant cardiac function. From June 1995 at the University of Tokyo, we have adopted a heart protective regimen (VP/rCY/TBI) which is composed of continuous infusion of VP-16 20 mg/kg for 2 days, CY 40 mg/kg for 1 day, and 12 Gy of fractionated total body irradiation (TBI) for 17 patients because they had impaired cardiac function defined by ejection fraction (EF) less than 0.55 (n=15) or a history of congestive heart failure (n=1) or pulmonary hypertension (n=1). The clinical relevance of VP/rCY/TBI regimen was evaluated by retrospectively comparing the outcome of VP/rCY/TBI recipients with that of conventional CY/TBI (CY 60 mg/kg for 2 days + fractionated TBI 12 Gy, which was administered to 140 patients during the same period) recipients. The characteristics analysis revealed that VP/rCY/TBI recipients had higher cumulative doses of anthracyclines (354 mg/m2 vs 150 mg/m2 calculated as the equivalence of native doxorubicin, p<0.0001), lower EF (0.51 vs 0.66, p=0.005), larger left ventricular end-systolic dimension (LVDs) (35 mm vs 30 mm, p<0.0001), and worse Karnofsky performance scales (KPS) (90 vs 100, p=0.0037) than CY/TBI recipients. There was no difference in the other characteristics between the two groups, including age, disease status, ferritin level, and the other UCG findings. The median follow up period for surviving patients was 43.9 months after transplantation (range: 4–146 months). Survival analysis was conducted considering non-relapse mortality (NRM) and relapse rates as competing risk factors of each other. The relapse rate was not significantly different between the two groups (p=0.24), which indicates that VP/rCY/TBI regimen has a comparable anti-tumor effect to standard CY/TBI regimen. In addition, despite poorer KPS and more cardiac co-morbidity in the VP/rCY/TBI arm, no difference in the NRM rates was observed between the two groups. Especially, it is noteworthy that Bearman grade III-IV cardiac toxicity within 28 days after HSCT was not significantly increased in VP/rCY/TBI group (one in VP/rCY/TBI recipients (5.9%) and five in CY/TBI recipients (3.6%), p=0.64). There was no significant difference in the incidence of grade II-IV (p=0.35) or grade III-IV (p=0.10) acute GVHD. From these results, we conclude that VP/rCY/TBI regimen can be safely administered for patients with pre-transplant cardiac co-morbidity while preserving anti-neoplastic effects.
4
Kekre, Natasha, Jennifer Philippe, Ranjeeta Mallick, Susan Smith, and David Allan. "Modelling Improvements in Cell Yield of Banked Umbilical Cord Blood and the Impact on Availability of Donor Units for Transplantation into Adults." Stem Cells International 2013 (2013): 1–6. http://dx.doi.org/10.1155/2013/124834.
Full textAbstract:
Umbilical cord blood (UCB) is used increasingly in allogeneic transplantation. The size of units remains limiting, especially for adult recipients. Whether modest improvements in the yield of cells surviving storage and thawing allow more patients to proceed to transplant was examined. The impact of improved cell yield on the number of available UCB units was simulated using 21 consecutive anonymous searches. The number of suitable UCB units was calculated based on hypothetical recipient weight of 50 kg, 70 kg, and 90 kg and was repeated for a 10%, 20%, and 30% increase in the fraction of cells surviving storage. Increasing the percentage of cells that survive storage by 30% lowered the threshold of cells needed to achieve similar engraftment rates and increased numbers of UCB units available for patients weighing 50 (P=0.011), 70 (P=0.014), and 90 kg (P=0.003), controlling for differences in HLA compatibility. Moreover, if recipients were 90 kg, 12 out of 21 patients had access to at least one UCB unit that met standard criteria, which increased to 19 out of 21 patients (P=0.035) when the fraction of cells surviving storage and thawing increased by 30%. Modest increases in the yield of cells in banked UCB units can significantly increase donor options for adult patients undergoing HSCT.
5
Corradini, Paolo, Anna Raganato, Cristiana Carniti, et al. "CD8-Depleted Donor Lymphocyte Infusions Can Boost Immune Reconstitution after Haploidentical Stem Cell Transplantation Following Reduced-Intensity Conditioning Regimen." Blood 108, no. 11 (2006): 3138. http://dx.doi.org/10.1182/blood.v108.11.3138.3138.
Full textAbstract:
Abstract Haploidentical stem cell transplantation (SCT) can be used in relapsed haematological malignancies for patients lacking a matched sibling or unrelated donor. Major barriers of this strategy are the poor immune reconstitution and the high risk of relapse. Here, we report results of a phase I–II trial evaluating early add-backs of CD8-depleted donor lymphocytes (DLIs) (from 1x10^4 up to 1x10^5 cells/kg starting at day+45 up to day +105 at monthly intervals) after a reduced intensity conditioning (RIC) regimen [thiotepa (10 mg/kg), fludarabine (120 mg/sqm), cyclophosphamide (60 mg/kg) and TBI (2 Gy)]. Ex-vivo and in-vivo TCD were carried out by CD34+ cell selection using the CliniMACS device and alemtuzumab (15mg/m2, day-2), respectively. Twenty-one patients [n= 10 NHL (n=5 CLL, n=5 high-grade NHL), n=7 HL, n=1 MM, n=1 ALL, n=2 AML] were transplanted with advanced disease: 16 (76%) failed a previous autograft and 13 (62%) had refractory disease. A median of 10.4x10^6/Kg CD34+, 1x10^4/kg CD3+, 10x10^4/kg CD19+, 0.9 x10^4/kg NK+ were infused. All patients engrafted with full donor chimerism from day +90. At a median follow-up of 12 months (range, 4–41 months), 12 of 21 pts are alive (7 CR, 2 PR and 3 PD) and 9 died [n=3 infection with GVHD (+610, +187, +253), n=6 disease]. The estimated 2-year overall survival was 49%: pts transplanted in remission had better outcome (83% versus 31%, p=0.13). The estimated 2-year cumulative incidence of TRM and relapse were 27% and 58%, respectively. CMV reactivation and hospital readmissions for opportunistic infections occurred in 76% and 57% of patients, respectively. For CD8 depletion of donor leukaphereses, a new depletion protocol using clinical grade CD8 microbeads (Miltenyi) was applied. This procedure is efficient to reduce the content of CD8 T cells by 3 logs while the median cell recovery of CD3+, CD4+, CD56+/CD3+, CD 20+ was 60%, 86%, 54%, 72%, respectively. Before DLIs, only 2 of 21 patients (10%) developed acute GVHD (no grade III–IV). A total of 36 CD8-depleted DLIs were administered to 17 pts without any acute toxicity. Following DLIs, 6 pts (35%) developed acute GVHD (grade II) and 5 (30%) chronic GVHD (n=2 limited, n=3 extensive). Overall, the incidence of acute GVHD is higher (50% vs 22%, p=0.33) in pts receving larger numbers of donor cells (10–15x10^4/kg versus 3–5x10^4/kg CD8-depleted DLIs). The median values of CD4+/uL, CD8+/uL and NK+ were 100, 280 and 680 at 4 months and 220, 200, 500 at 6 months after SCT in patients receiving CD8-depleted DLIs. Measurable TREC/ucg DNA (mean value 316; mean value donors 3740) and polyclonal T cell repertoire, evaluated by spectratyping, were observed at 9 months in patients younger than 40 years and/or without GVHD. Our results suggest that: haploidentical SCT with RIC regimen provides high engraftment rate T-cell addback allows the achievement of more than 100/uL CD4+ at 4 months after SCT in the majority of patients Survival rate is promising in patients who had transplantation in remission suggesting that this strategy should be evaluated earlier in high risk haematological diseases.
6
Waller, Anthony F., Fengrong Wang, and Ned Waller. "A Mathematical Model of Stochastic Engraftment by Non-Interacting Single Umbilical Cord Blood (UCB) Grafts Predicts Accelerated Engraftment Using Multiple UCB Grafts." Blood 110, no. 11 (2007): 2034. http://dx.doi.org/10.1182/blood.v110.11.2034.2034.
Full textAbstract:
Abstract Background: The use of UCB transplants is limited by the difficulty of finding units with sufficient cells to provide reliable engraftment, and the slower kinetics of hematopoietic engraftment compared to other hematopoietic progenitor cell grafts. Grafts consisting of two unrelated UCB result in accelerated engraftment compared to single unit UCB transplants, but the mechanism for enhanced engraftment is unknown. Methods: We extracted data from published studies on myeloid engraftment following transplantation of single (9 studies, 1542 engrafted patients) or double (4 studies, 94 engrafted patients) UCB units (Table). A weighted average of median days (and estimated SD) to engraft for single and double UCB transplants was calculated. The cumulative incidence of myeloid engraftment for single or double UCB transplants was modeled based the assumption that the time to engraft was described by a normal distribution. For double and triple UCB transplants, the probability of myeloid engraftment at any time post-transplant was calculated as 1 minus the probability of non-engraftment for a single UCB unit squared or cubed, respectively. Results: The weighted average percentage for myeloid engraftment following single UCB transplants was 89%, with a median day of engraftment of 26.4 days. The weighted average for the rate of myeloid engraftment following double UCB transplants was 96%, with a median day of engraftment of 22 days. The calculated median days to engraft from single or double UCB transplants, using the assumption of normal distributions, were 22 and 26 days, respectively. Applying the mathematical model, the predicted cumulative engraftment for a double UCB graft is 99%, with a the curve for cumulative engraftment kinetics quite similar to the observed engraftment in Barker 2005 and the calculated curve for double UCB transplants based upon analysis of extracted data (Figure). Conclusion: UCB units do not appear to facilitate engraftment in grafts containing multiple units. A stochastic statistical model, in which different UCB grafts engraft independently, appears to account for the observed 4-day decrease in the median time to achieve myeloid engraftment following a double versus single UCB transplant. The use of a triple UCB graft is predicted to shorten the median time to achieve neutrophil engraftment to a median of 20 days. Published experiences describing myeloid engraftment following single and double UCB transplants Single UCB Transplant N, % engrafted Median day to engraft Double UCB Transplants N, % engrafted Median day to engraft Laughlin NEJM 2001 N=61, 90% 27 Barker Blood 2005 N=50, 100% 23 Hamza BJH 2004 N=28, 86% 29 Yoo ASH 2005 N=12, 100% 23 Barker Blood 2001 N=31, 88% 26 Kai ASH 2004 N=11, 82% 21 Thomson Blood 2000 N=30, 81% 25 Ballen ASH 2005 N=21, 90% 20 Sanz Blood 2001 N=22, 100% 22 Terakura BBMT 2007 N=148, 81% 22 Wagner Blood 2002 N=102, 86% 22 Migliaccio Blood 2000 N=200, 91% 28 Stevens Blood 2002 N=1111, 90% 27 Figure Figure
7
Chehrazi-Raffle, Alexander, Tanya B. Dorff, Sumanta K. Pal та Yung Lyou. "Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma". Cancers 13, № 4 (2021): 889. http://dx.doi.org/10.3390/cancers13040889.
Full textAbstract:
Urothelial cell carcinoma (UCC) is a significant public health burden. It accounts for approximately 90 percent of all bladder cancers with an estimated 200,000 annual deaths globally. Platinum based cytotoxic chemotherapy combinations are the current standard of care in the frontline setting for metastatic UCC. Even with these treatments the median overall survival is estimated to be about 15 months. Recently, immune checkpoint inhibitors (ICIs) have demonstrated superior clinical benefits compared to second line chemotherapy in UCC treatment. However only a minority of patients (~20%) respond to ICIs, which highlights the need to better understand the mechanisms behind resistance. In this review, we (i) examine the pathophysiology of Wnt/β-catenin signaling, (ii) discuss pre-clinical evidence that supports the combination of Wnt/β-catenin inhibitors and ICI, and (iii) propose future combination treatments that could be investigated through clinical trials.
8
Chow, Robert, David Gjertson, Joseph Rosenthal, et al. "Clinical Outcome of Hematopoietic Stem Cell Transplantation (HSCT) Using Plasma Depleted Umbilical Cord Blood Units (UCB) That Were Not Depleted of Red Blood Cells Prior to Cryopreservation." Blood 106, no. 11 (2005): 2045. http://dx.doi.org/10.1182/blood.v106.11.2045.2045.
Full textAbstract:
Abstract Background: UCB is an attractive source for HSCT because of less stringent HLA matching requirements, lower incidence and severity of GvHD, and ready availability of a physical inventory. However, unlike BMT or PSCT, the limiting cell dose associated with UCB units has hampered its widespread use. The red cell depletion (RCD) techniques that are widely used by UCB banks incur significant nucleated cell loss after processing. One method of minimizing cell loss during processing is to deplete plasma (PD) but not red blood cells. A large racially diverse inventory of 18,000 PD UCB is now available on stem cell registries; however, clinical outcome for HSCT using PD UCB products is unavailable. Hypothesis: Usage of PD UCB in unrelated HSCT will result in acceptable clinical outcome for myeloid (ANC 500) and platelet engraftment, overall survival (OS), event-free-survival (EFS), and transplant related mortality (TRM). Methods: A retrospective analysis limited to patients without prior transplants and transplanted during remission (“eligible”) was performed on 98 HSCT using PD UCB. An additional 20 “high risk” patients with prior transplants or transplanted during relapse were included in the engraftment and survival analysis. Results: Average loss of less than 0.1% nucleated cells was found in the discarded plasma fraction after PD UCB processing (n=27), though cell clumping limited the cellular fraction recovery to 90%. Outcome on engraftment and/or survival was available for 98 patients (median age 6.7 yo, range 0.3–54 yo, 24 >16 yo; median weight 23.5 kg, range 4.5–88 kg, 27 >50kg; male 60%; median # HLA ABDR matches 4.0; median pre-freeze TNC dose 5.7 x 107/kg; transplant center reported median post-thaw TNC dose 5.5 x 107/kg; median pre-freeze CD34 dose 2.0 x 105/kg; malignant indications 71%; transplants outside U.S. 37%; double unit transplant 14%; and non-myeloablative 7%). The median time to engraftment for ANC 500 (n=87), platelet 20K (n=72) and 50K (n=68) were 22.0 days (range 7–49 days), 49.5 days (range 13–94 days), and 58.0 days (range 21–132 days) respectively. The unadjusted cumulative incidence of ANC500 and platelet 20K and 50K engraftment were 94±3%, 81±5% and 80±5% respectively for 98 eligible patients, and 90±3%, 77±5% and 75±5% respectively for the eligible plus high risk patients. The incidence of grade III–IV acute GVHD and extensive chronic GVHD were 15% and 14% respectively. Relapse rate for malignancies (n=67) and TRM (n=98) were 20±6% and 20±4% respectively at 1 year. With a median follow-up of 297 days (range 50–1,263 days), the Kaplan-Meier estimates of 1-year survival (n=98) and disease-free survival (n=67) are 73±5% and 59±7% respectively for the eligible patients, and 65±5% (n=118) and 50±6% (n=85) respectively for the eligible plus high risk patients. Conclusion: These results demonstrate that HSCT using PD UCB can be performed safely and effectively.
9
Lauritzen, Esben S., Thomas Voss, Ulla Kampmann, et al. "Circulating acylghrelin levels are suppressed by insulin and increase in response to hypoglycemia in healthy adult volunteers." European Journal of Endocrinology 172, no. 4 (2015): 357–62. http://dx.doi.org/10.1530/eje-14-0880.
Full textAbstract:
ObjectiveGhrelin has glucoregulatory and orexigenic actions, but its role in acute hypoglycemia remains uncertain. We aimed to investigate circulating levels of acylghrelin (AG) and unacylated ghrelin (UAG) in response to hyperinsulinemia and to hypoglycemia.DesignA randomized, single-blind, placebo-controlled crossover study including 3 study days was performed at a university hospital clinical research center.MethodsNine healthy men completed 3 study days: i) saline control (CTR), ii) hyperinsulinemic euglycemia (HE) (bolus insulin 0.1 IE/kg i.v. and glucose 20% i.v. for 105 min, plasma glucose ≈5 mmol/l), and iii) hyperinsulinemic hypoglycemia (HH) (bolus insulin 0.1 IE/kg i.v.).ResultsHH and HE suppressed AG concentrations at t=45–60 min as compared with CTR (P<0.05). At t=90 min, a rebound increase in AG was observed in response to HH as compared with both HE and CTR (P<0.05). UAG also decreased during HH and HE at t=45 min (P<0.05), whereas the AG-to-UAG ratio remained unaffected.ConclusionsThis study demonstrates that AG and UAG are directly suppressed by hyperinsulinemia and that AG concentrations increase after a latency of ≈1 h in response to hypoglycemia, suggesting a potential counterregulatory role of AG.
10
Mcinnes, I., P. J. Mease, K. Eaton, et al. "AB0820 COMPARATIVE EFFICACY OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1713–14. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6013.
Full textAbstract:
Background:The efficacy of the interleukin (IL)-23 subunit p19 inhibitor guselkumab (GUS) for psoriatic arthritis (PsA) has recently been demonstrated in two Phase 3 trials (DISCOVER-1 & -2) but has not been evaluated versus existing targeted therapies for PsA.Objectives:To compare GUS to targeted therapies for PsA through network meta-analysis (NMA).Methods:A systematic literature review was performed to identify PsA randomized controlled trials from 2000 to 2018. Bayesian NMAs were performed to compare treatments on American College of Rheumatology (ACR) 20/50/70 response, Psoriasis Area Severity Index (PASI) 75/90/100 response, Health Assessment Questionnaire Disability Index (HAQ-DI) score, resolution of enthesitis (RoE), resolution of dactylitis (RoD), adverse events (AEs) and serious adverse events (SAEs). Analyses used random effects models that adjusted for placebo response via meta-regression on baseline risk when feasible. Results are summarized by ranking treatments according to median absolute probabilities of response derived from NMAs.Results:Twenty-six Phase 3 studies were included in the quantitative synthesis. Studies were placebo-controlled up to 24 weeks and evaluated 13 targeted therapies for PsA. Absolute probabilities are reported for PASI 90 & ACR 20 responses according toFigure 1,and a forest plot of relative risks versus placebo for AEs is reported according toFigure 2. For ACR 20 response, GUS 100 mg every 4 weeks (Q4W) and every 8 weeks (Q8W) ranked 5th and 8th out of 20 interventions and were comparable to IL-17A inhibitor (IL-17Ai) and most tumor necrosis factor inhibitor (TNFi) agents. Similar findings were observed for ACR 50 and 70 responses. For PASI 90 response, GUS Q4W and Q8W ranked 1st and 2nd out of 15 interventions and were highly likely to provide a greater benefit than most other agents. Similar findings were observed for PASI 75 and 100 responses. For HAQ-DI score, GUS Q4W and Q8W ranked 6th and 10th out of 20 interventions and were comparable to IL-17Ai and most TNFi agents. For RoE, GUS Q4W and Q8W ranked 8th and 6th out of 13 interventions and were comparable to IL-17Ai and TNFi agents. For RoD, GUS Q4W and Q8W ranked 8th and 9th out of 13 interventions and were comparable to most IL-17Ai and TNFi agents. For AEs, GUS Q4W and Q8W ranked 3rd and 2nd out of 19 interventions and were comparable to IL-17Ai and TNFi agents. Likewise, for SAEs, GUS Q4W and Q8W ranked 4th and 5th out of 20 interventions and were comparable to IL-17Ai and TNFi agents. Analyses that controlled for previous exposure to biologics or assessed outcomes at alternative timepoints were broadly consistent with primary analysis results.Conclusion:NMA results indicate that GUS is comparable to most targeted PsA treatments for improvement in arthritis, soft tissue damage, physical function, and safety outcomes. For PASI outcomes, GUS is highly likely to provide a greater benefit than other targeted PsA treatments.Disclosure of Interests:Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB, Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau, Kiefer Eaton Shareholder of: Test Pharma, Consultant of: Janssen, Agata Schubert Employee of: Janssen-Cilag, Steve Peterson Employee of: Janssen Research & Development, LLC, Tim Disher Consultant of: Janssen, Wim Noel Employee of: Janssen Pharmaceuticals NV, Hassan Fareen Employee of: Janssen, Chetan Karyekar Shareholder of: Johnson & Johnson, Consultant of: Janssen, Employee of: Janssen Global Services, LLC. Previously, Novartis, Bristol-Myers Squibb, and Abbott Labs., Suzy Van Sanden Employee of: Janssen, Christopher T. Ritchlin Grant/research support from: UCB Pharma, AbbVie, Amgen, Consultant of: UCB Pharma, Amgen, AbbVie, Lilly, Pfizer, Novartis, Gilead, Janssen, Wolf-Henning Boehncke Grant/research support from: Janssen Research & Development, LLC, Consultant of: Janssen
Books on the topic "UCG 90-20"
Conference papers on the topic "UCG 90-20"
1
Sánchez Alamina, Arcelia del Carmen, Irene Carrillo Salgado, Jorge Joaquín Cantó Ibañez, and José Juan Carlos Sánchez Ghenno. "Effects of Phosphonates in the Microbiological Activity of SRB and APB in Oil Fields." In CORROSION 2015. NACE International, 2015. https://doi.org/10.5006/c2015-05689.
Full textAbstract:
Abstract Biocorrosion of metal pipelines in the oil and hydrocarbon industry is frequently linked to the presence of Sulfate Reducing Bacteria (SRB) and Acid Producing Bacteria (APB). Suggested mechanisms of SRB induced corrosion are an accumulation of corrosive metabolites like hydrogen sulfide or cathodic depolarization. The APB produce organic acids as results of its metabolism. A biocide can be defined as a chemical agent that is capable of destroying living organisms. Microbiological studies have been conducted in the field to assess the efficiency of a biocide with a base of phosphonate derivatives. Tests performed were microbiological analysis of APB and SRB inoculation by taking a liquid sample directly from an oil field well. After incubation, the colonies were counted per ml of sample (UCF). Positive APB and SRB samples were selected for inoculations tests in the presence and absence of biocide. Tests were performed at four concentrations (50 ppm, 100 ppm, 150 ppm and 200 ppm) of the sample liquid bactericidal at different times (0, 10, 20, 40, 60, 80, 100 and 120 minutes). High bactericidal efficiency values for the biocide were recorded exceeding the 96% efficiency from the 100 ppm concentration. The bactericidal proved highly effectiveness inhibiting the growth of SRB with no registered value greater than 10 cfu / ml, indicating greater than 90% efficiency. The active principle of the biocide tested (phosphonate derivatives), proved consistency over time, preventing bacterial growth in the 8 timelines.
2
Chin, Ken S., Mark S. Mongon, Clyde H. Delvin, and Regional Director. "Demolition of the Elevated Central Artery." In SSPC 2003. SSPC, 2003. https://doi.org/10.5006/s2003-00011.
Full textAbstract:
Abstract The Massachusetts Highway Department and Massachusetts Turnpike Authority, under the auspices of the United States Department of Transportation, Federal Highway Administration, are nearing the completion of the construction of a 7.5 mile urban highway corridor which will replace Boston’s elevated Central Artery (Interstate 93) with a new eight to ten lane underground expressway, and a new four lane tunnel (Interstate 90) beneath Boston Harbor connecting South Boston to Logan International Airport. The existing Elevated Artery, a deteriorated six-lane highway built in the 1950’s, traverses downtown Boston through a densely populated urban setting comprised of historical tourist attractions, financial/business districts, and residential neighborhoods. The Dewey Square Tunnel, built at the same time, is a _ mile tunnel directly connecting the Elevated Artery to Interstate 93. Once the northbound of the underground expressway is opened for traffic to the general public in early 2003 and the southbound in 2004, the elevated portion of the Central Artery will be demolished and will be replaced by 27 acres of new open spaces. Dewey Square Tunnel will also undergo extensive reconstruction in order to mesh with the newly constructed underground expressway. The Elevated Artery and Dewey Square Tunnel are constructed of structural steel and concrete. The structural steel is coated with multiple layers of lead based paint containing approximately 20-35 percent lead. Due to the age of the structure and weathering, paint delamination has occurred on numerous areas of the structural steel. Preparation has been underway to abate the lead-based paint prior to demolition/reconstruction. Given the densely populated urban setting, The Project has adopted a comprehensive approach in managing the lead-paint abatement, with ambient air monitoring at the fence line for the protection of public health as the main component of the management program. The driving force behind this approach is the Threshold Exposure Limit (TEL), established by the Massachusetts Department of Environmental Protection (MADEP) specifically for the CA/T project. The TEL is 0.14 ug/m3 of lead averaged over a 24-hour period, significantly more stringent than the NAAQS standard of 1.5 ug/m3 of lead averaged over a 90-day period. This paper focuses on the results of the ambient air-monitoring program, the specific LBP removal methods that are required to keep ambient air levels below the TEL, and the corrective actions taken when an exceedance of the TEL is encountered.
3
BOUTHERIN-FALSON, O., and N. BLAES. "MODULATION of PROSTACYCLIN PRODUCTION BY HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS WITH ECGF/HEPARIN MEDIUM : ROLE OF CELLULAR DENSITY AT CONFLUENCE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643376.
Full textAbstract:
Prostacyclin (PGI2) is a major product of arachidonic acid metabolism in vascular endothelial cells. In addition to the role of exogenous agents, its production could be modulated by culture conditions : proliferative state, medium renewal, subcultivation... The use of endothelial cell growth factor (ECGF) associated with heparin has been shown to improve human endothelial cell proliferation. Here we report that human umbilical vein endothelial cells (HUVEC) grown in that medium produce less prostacyclin than without growth factor.HUVEC were cultured in RPMI-199 1:1 + 20% fetal calf serum, added or not with ECGF (Bovine hypothalamus extract BTI Cambridge, 24 ug/ml) and heparin (from porcine intestinal mucosa, Signa, 90 ug/ml). After 4 days in culture, medium was removed and replaced by Tyrode Hepes buffer and basal production was measured after 20 min. Cells were then submitted to 5 min thrombin to assess PGI2 production in stimulated conditions. PGI2 production was estimated by specific radioimmunoassay for 6 keto PGFjalpha. For each point, cell number in the culture was counted after Trypsin EDTA treatment. In the present study, cells grown in ECGF-heparin medium produce lower amount of PGI2, compared to heparin or control medium. This result was observed in both basal and stimulated conditions. For each medium (ECGF-heparin, heparin, control), correlations between PGI2 production per cell and log cell density were shown to be significantly negative.These observations suggest that ECGF effect on PGI2 production could be a consequence of its growth factor activity, notably by the fact that it leads to an endothelial monolayer made of more numerous cells. Since it is now suggested by a number of clinical observations that PGI2 is rather produced in pathological conditions, culture models showing a weak production of PGI2 appear in that connection doser to the physiological conditions.
4
Stump, D. C., E. J. Topol, R. Califf, A. B. Chen, A. Hopkins, and A. D. Collen. "RESULTS OF COAGULATION - FIBRINOLYSIS ANALYSES IN 386 PATIENTS WITH ACUTE MYOCARDIAL INFARCTION TREATED WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR (rt-PA) (TAMI TRIAL)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643746.
Full textAbstract:
Three hundred eighty-six patients with acute myocardial infarction received up to 150 mg rt-PA (single chain) IV either over 8 h (60mg over 1 h, 20 mg/h for 2 h,10 mg/h for 5 h)(173 pts) or over"5h(1 mg/kg over 1 h, remainder over 4 h) (213 pts),before randomization to early or late angioplasty. Blood was collected on a lyophilized mixture of citrate and the t-PA inhibitor D-Phe-Pro-Arg-CH2C1 (PPACK), to maximally prevent in vitro fibrinolytic activation and concomitant fibrinogen degradation. The plasma rt-PA level increased to 2.4±2.0 /μg/ml(mean +SD)and 1.7 ±1.3 /μg/ml after 3h and to 1.0 ±1.8 and 1.0 ±0.9 /μg/ml at the end of the infusion.Fibrinogen levels (coagulation rate assay) fell to 5 ± 28 and 52 ± 27% at 3 h and to53 ± 28 and 47 μ 26% at the endof infusion.Fibrinogen degradation productsincreased to 32 /μg/ml (median, with 10 and 90 percentile values of 2 and 512 /μg/ml) after 3h and to3 2 /μg/1 (median, with 10 and 90 percentile values of 2and 512 ug/ml) at the end of infusion. The fibrinogen decreased to below 1 g/1 in 23% of patients and b e low 0-5 g/1 in 11% after 3 h infusion with corresponding values of 33% and 12%at the end of infusion.Thus, at the infusion rates required for rapid coronary artery reperfusion in man, rt-PA remains relatively fibrin-specific. The cause of the extensive fibrinogen depletion occurring in some patients remains to be further investigated.
5
Ifrene, Ghoulem, Prasad Pothana, Sven Egenhoff, Neal Nagel, and James Hickey. "Investigating Mechanical and Acoustic Properties of 3D Printed Materials: A Focus on Printing Orientation." In 58th U.S. Rock Mechanics/Geomechanics Symposium. ARMA, 2024. http://dx.doi.org/10.56952/arma-2024-1073.
Full textAbstract:
ABSTRACT: Stereolithography (SLA) 3D printing technology is increasingly applied in geomechanics, petroleum engineering, geothermal, and CO2 storage research, particularly in fracture flow and mechanics. To understand the mechanical characteristics of 3D printed materials, we conducted laboratory experiments examining the effect of printing orientation on the properties of three specimens. These specimens were printed using a FormLabs (3B+) 3D printer at layering angles of 0°, 45°, and 90°, with a resolution of 100μm, and sized 1-inch in diameter and 2-inches in length. We performed triaxial compressive tests, ultrasonic elastic wave velocity measurements, and unconfined compressive strength (UCS) tests using an Autolab 1500 test frame. Incremental confining pressures from 1 MPa to 20 MPa were applied to explore static and dynamic mechanical properties. The UCS tests showed that all samples exhibited ductile behavior with similar stiffness and yield strength across different layering angles, demonstrating a stiffness of approximately 4 GPa and compressional wave velocities between 2555-2580 m/s at zero confining pressure. The findings confirm the mechanical and acoustic consistency of the samples, supporting their suitability for advanced geomechanical applications. 1. INTRODUCTION Three-dimensional (3D) printing technology, also known as advanced manufacturing (AM), is a rapidly developing field that has revolutionized manufacturing processes across various industries including aerospace (Richter & Lipson, 2011), automotive (Rahim & Maidin, 2014), healthcare (Logan & Duddy, 1998), petroleum engineering (Li et al., 2021), and geomechanics (Phillips et al., 2021). This technology uses computer-aided design (CAD) to create three-dimensional objects by adding material layer by layer using almost any type of material such as polymers, and ceramics. Thermoplastic urethane and metals can also be employed as raw material (Gopinathan & Noh, 2018). There are several techniques involved in 3D printing, including Fused Deposition Modeling (FDM), Stereolithography (SLA), Selective Laser Sintering (SLS), Digital Light Processing (DLP), Binder Jetting, and Material Jetting. Each technique has its advantages and disadvantages (Jandyal et al., 2022), and the choice of technique depends on the type of object being printed, the desired resolution, and the available materials. With the increasing popularity and availability of 3D printing technology, it is now relatively easy to create custom objects, prototypes, and even entire structures using 3D printing. Among the available techniques, SLA is known for producing high-resolution objects with smooth surfaces. SLA was first developed in the early 1980s by Kodama, 1981 and called Rapid Prototyping (RP).
6
MacGregor, I. R., E. Roberts, C. V. Prowse, N. A. Booth, A. Broomhead, and P. Litka. "CHANGES IN PLASMA t-PA, PAI AND FACTOR VIII FOLLOWING I. V. AND S. C. INJECTION OF DDAVP IN HEALTHY VOLUNTEERS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644133.
Full textAbstract:
DDAVP is used effectively to induce a haemostatic response in certain types of haemophilia A and von Willebrands disease, but the accompanying increase in fibrinolytic activity is an unwanted effect. Here we have quantified the extent and time course of changes in t-PA, its physiological inhibitor PAI and factor VIII moieties, using functional and immunometric assays, following i.v. and s.c. injection of DDAVP 0.4 ug kg-1 in 6 normal volunteers in a double blind crossover study.T-PA, factor VIII and vWF values increased after dosing and the area under the response versus time curve was higher after i.v. than s.c. injection. Conversely levels of PAI activity decreased, with lower minimum values for i.v. than s.c. and a correspondingly lower area under the response curve for the former route. In several subjects PAI activity fell to zero during the sampling period. The times to the first occurrence of maximum response were determined. The median values for factor VIII were 40 and 90 min for i.v. and s.c. respectively. For vWF they were 60 and 80 min. For t-PA activity they were 20 and 60 min indicating that the release of factor VIII and vWF was delayed compared with t-PA activity. PAI-1 antigen was assayed by ELISA to investigate clearance of PA inhibitor and was compared with changes in PAI activity during the infusion of DDAVP and after a subsequent venous occlusion.The results indicate that fibrinolytic and haemostatic responses follow different time courses from each other, both after i.v. and s.c. administration of DDAVP, that are reproducible from subject to subject. The use of specific assays has permitted determination of the fibrinolytic response to DDAVP to be assessed in terms of changes in pro and antifibrinolytic components.
7
Bianchini, P., R. Nonn, J. Fareed, J. M. Walenga, and A. Kumar. "STUDIES ON THE ANTITHROMBOTIC ACTION OF A LOW MOLECULARWEIGHT HEPARIN OBTAINED FROM BEEF MUCOSAL ORIGIN AND PEROXIDATIVE CLEAVAGE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644164.
Full textAbstract:
We have studied a low molecular weight heparin (LMWH) obtained by acontrolled peroxidative depolymerization of beef mucosal heparin (OP 2123, Opocrin, Corlo, Italy). This product was found to be significantly different from other LMWHs in that it exhibits the same COO-/SO2- ratios as unfractionated heparin, contains reducing end groups composed of 2-sulfated iduronic acid or 6-disulfated glucosamine and retains an identical structural integrity as that of native heparin. As opposed to most other LMWHs the oligosaccharide components of OP 2123 consist of homogeneous progressive units. In addition, the relative amount of AT-IIIaffinity components in OP 2123 were 20-30% less than other LMWHs. OP 2123 has a mean molecular weight of 6200 daltons with a potency of 90 anti-factor Xa U/mg and 68 USP U/mg. This agent produced strong antithrombotic actions in a rabbit stasis model against both an activated prothrombin complex and a prothrombin complex concentrate/Russell's viper venomcombination (ED50:(IV) 30-70 ug/kg;(SC) 0.6-1.5 mg/kg). The antithrombotic effects were comparable to other LMWHs in normal rabbits: however, in AT III depleted rabbits (immunodepleted and y thrombin depleted), OP 2123 produced stronger antithrombotic effects than most other LMWHs. The in vitro systems in contrast to other LMWHs, CP 2123 produced stronger inhibitory effects in AT III depleted plasma as measured by fibrinopeptide A generation and amidolytic anti-factor Xa and anti-factor Ila methods. The relative heparin cofactor II activity as measured by amidolytic method was also found to be higher than with most LMWHs. These results suggest that OP 2123, unlike most LMWHs, non AT III mediated actions play a major role in themendiation of the antithrombotic actions.
8
Melo, Maria Eduarda Bernardino Martins, Gabriela Prado Lopes, Darley Lima Ferreira Filho, Irnanda Layanna Gomes Oliveira, and Maria Eduarda Vasconcelos Florêncio Cavalcanti. "MALE BILATERAL BREAST CANCER: CASE REPORT." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1077.
Full textAbstract:
Introduction: Breast cancer occurring bilaterally in men is extremely rare. Breast cancer represents 1% of all cancers, while bilateral cancer represents 5% of a total number of patients with breast cancer, which may be synchronic or metachronic. Many cases of breast cancer in men are detected between 60 and 70 years, with an average of 67 years of age. In men there is a tendency for late diagnosis at a more advanced stage than in women. Case report: A male patient, JSS, 68 years old, from Afogados da Ingazeira, state of Pernambuco, was seen with breast tumoration in June 2016. He arrived at the service with an existing diagnosis of breast cancer through core-biopsy examination. The physical exam presented bulging in the left retroareolar region and a hardened tumoration in palpation. Radical mastectomy was performed. The histopathological results confirmed an invasive mucinous carcinoma with histological grade I, nuclear grade II and mitotic grade I. Free margins. The most frequent histological type in men is ductal (85%–90%), followed by papillary in 4.5% and mucinous in 2.8% of the cases. Nineteen free axillary lymph nodes were dissected, with Estrogen and Progesterone + receptors, Her-2, negative and with Ki-67 of 5%. Breast cancers in men present with more positivity for hormone receptors and low expression for Her-2. The pathological staging was classified as II a. The patient was being followed by the clinical oncology department, where he was chosen not to do chemotherapy and only hormone therapy, with Tamoxifen 20 mg. However, over a period of six months he noticed the presence of a tumoration in the right breast. An image examination was performed with MG/USG, which confirmed the presence of a tumor in the right retro-areolar region (Birads IV). A core-biopsy of the lesion was requested, which confirmed an invasive breast cancer. The patient underwent right radical mastectomy, whose result confirmed an invasive ductal carcinoma with pathological staging II a. Conclusion: This pathology is extremely rare in men and the evaluation of the contralateral breast is of fundamental importance. Early diagnosis and compliance with treatment will reduce tumor recurrence and provide a better prognosis for these patients.